Custom health and wellness using regenerative therapies
Tissue/Cells ability to differentiate and secrete trophic factors has important potential for tissue regeneration and repair.
Stem cell paracrine actions and tissue regeneration.
Baranaki PR & McDevitt TC. Regenerative Medicine. 2010 Jan.
Abstract Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833273/
Having a big sale, on-site celebrity, or other event? Be sure to announce it so everybody knows and gets excited about it.
Tissue treatment was found to produce significant improvement in a large study of patients with rheumatoid arthritis according to validated questionnaires.
Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy.
Wang et al. Stem Cells Development. 2013 Dec.
Abstract Link: https://pubmed.ncbi.nlm.nih.gov/23941289/
Local injection of mesenchymal stem cells has been shown to improve joint function due to stem cells’ ability to repair and regenerate cartilage tissue.
Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial.
Jo CH et al. Stem Cells. 2014 May. Abstract
Safety and Complications Reporting on the Re-implantation of Culture-Expanded Mesenchymal Stem Cells using Autologous Platelet Lysate Technique.
Centento CJ. Current Stem Cell Research & Therapy. 2010. Abstract
Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial.
Saw KY et al. Arthroscopy. 2013 Apr. Abstract
Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells.
Centeno CJ et al. Pain Physician. 2008 May. Abstract
Partial regeneration of the human hip via autologous bone marrow nucleated cell transfer: A case study.
Centeno CJ et al. Pain Physician. 2006 Jul. Abstract
Immunomodulation is a key property of regenerative therapy cells that allows them not to elicit a patient immune response. Studies show that umbilical cord cells are safe and comparable to bone marrow derived cells, with great potential for therapeutic use.
Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions.
Girdlestone J et al. Cytotherapy. 2019. Abstract
In vitro immunologic properties of human umbilical cord perivascular cells.
Ennis J et al. Cytotherapy. 2008. Abstract
Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue.
Stubbendorff M et al. Stem Cells Development. 2013 Oct. Abstract
CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells.
Wang D et al. Experimental Cell Research. 2010 Sep. Abstract
The tissue regenerative properties of stem cells make them a unique tool for repairing cartilage after injury, serving as an alternative to surgery. Stem cells’ action on cartilage can reduce pain and improve joint function for patients who have suffered joint injuries.
In the human body, stem cells participate in bone healing after a fracture. Harnessing their osteogenic properties, stem cell treatment can aid in bone union to improve fracture recovery.
Arthritis is a condition of the joints that can become debilitating due to pain and decreased range of motion. While manifestations of arthritis differ from patient to patient, the underlying cause is chronic systemic inflammation. Mesenchymal stem cells are anti-inflammatory, allowing them to reduce the impact of arthritis. Studies that used stem cells to treat knee osteoarthritis have found the treatment to help patients to walk longer and climb more stairs, and have observed long-term improvement at 5-year follow-up, compared to baseline.
References for Arthritis Data:
Stem cell therapies have great potential in treating a range of chronic conditions. This site serves to inform people about stem cell regenerative medicine, stem cell products, and products that help support healthy cells.
While umbilical cord stem cell products are produced in an FDA compliant laboratory, they have not been approved by the FDA for treatment effectiveness. Stem cell products are governed by FDA CFR Title 21 1271 Rule 361 for HUCT’s.
The FDA states: Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.
If you are interested in stem cell therapy, consult with our healthcare providers.
Licensed medical professionals are available for consultations to discuss your specific needs so you can decide if regenerative medicine and stem cell therapy are right for you, as well as integrative nutrition methods. Your health is an extremely personal decision. The best investment you can make is in your health. As with structured diets, health coaches, trainers, gyms, yoga, and holistic medicine there are costs not currently covered by insurance.
https://pubmed.ncbi.nlm.nih.gov/23572051/ (Read more by clicking on the study link)
Neuropathic pain is a chronic condition that is heterogeneous in nature and has different causes. Different from and more burdensome than nociceptive pain, neuropathic pain more severely affects people's quality of life. Understanding the various mechanisms of the onset and progression of neuropathic pain is important in the development of an effective treatment. Research is being done to replace current pharmacological treatments with cellular therapies that will have longer lasting effects. Stem cells present an exciting potential therapy for neuropathic pain. In this review, we describe the neuroprotective effects of stem cells along with special emphasis on the current translational research using stem cells to treat neuropathic pain.
IS THIS FDA APPROVED?
Regenlife Tissue Therapy offers state-of-the-art stem cell procedures and utilizes “361” FDA compliant unmanipulated, homologous biomolecules and rich tissue grafts, 361 products that meet all the criteria outlined in 21 CFR 1271.10(a) are regulated as HCT/Ps and are not required to be licensed or approved by the FDA. These products are called “361 products,” because they are regulated under Section 361 of the Public Health Service (PHS) Act.
Human cells, tissues, and cellular and tissue-based products (HCT/Ps) consist of human cells or tissues intended for implantation, transplantation, infusion or transfer into a human recipient.
These ingredients have the potential to boost your body's ability to heal damaged cells and tissues and could help you recover more quickly.
OverviewHuman cells, tissues, and cellular and tissue-based products (HCT/Ps) consist of human cells or tissues intended for implantation, transplantation, infusion or transfer into a human recipient. The Food and Drug Administration regulates a cellular therapy product solely as an HCT/P (i.e. "361 product") if it meets all the following criteria in 21 CFR 1271.10(a):The product is minimally manipulated.The product is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article — except for water, crystalloids or a sterilizing, preserving or storage agent — provided that the addition of water, crystalloids or the sterilizing, preserving or storage agent does not raise new clinical safety concerns with respect to the HCT/PAnd either: Does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, orHas a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and is forAutologous useAllogeneic use in a first or second-degree relative orReproductive use.HCT/Ps are subject to the regulations in 21 CFR 1271 including establishment registration, donor eligibility (donor screening and testing), Current Good Tissue Practice (CGTP), additional regulatory requirements (adverse reaction reporting, HCT/P deviation reporting and labeling), and exemptions and alternative procedures. The regulatory requirements for allogeneic products are more extensive than for autologous products but, in general, FDA regulations emphasize preventing the risk of communicable disease transmission by HCT/Ps. Premarket review (licensure, clearance, and approval) by the FDA is not required for HCT/Ps.Examples of HCT/Ps are listed below:BoneHeart valve, Manipulated autologous chondrocytes, Ligament, Cornea, Hematopoietic progenitor(stem) cells (HPC) from peripheral and cord blood, Skin, Semen, Decellularized particulate human placental connective tissue matrix, Epithelial cells on a synthetic matrix, Other reproductive tissue, Dura mater,
AABB's Standards for Blood Banks and Transfusion Services defines accreditation requirements for facilities involved in collecting, processing, distributing, and transfusing blood and blood components. Because blood centers and transfusion services may store and dispense tissues (i.e., bone, ligament, and skin), these products are addressed in the general quality system requirements of the AABB Standards.
Although the FDA requires tissue banks to track tissues from the donor to the consignee (or final disposition), hospitals are considered exempt from this requirement.
AABB and other standards and accreditation programs have been working to implement ISBT-128 labeling — a standardized system widely used in the blood banking, tissue and cellular therapies industries — to preserve the traceability of tissue products. Activities related to the preparation and dispensing of tissues and associated record-keeping requirements are addressed in AABB's Standards.
HPCs can be obtained from different sources (marrow, cord blood, peripheral blood) and are used in a variety of therapeutic applications. HPC from marrow is regulated by the Health Resources and Services Administration, and HPC from peripheral blood collected by apheresis is regulated as an HCT/P.
Currently, the FDA’s Center for Biologics Evaluation and Research (CBER) is responsible for regulating HCT/Ps and it has two different paths for cell therapies that it constructed to reflect what it considers to be “relative risk”. These pathways are commonly called “361” and “351” products.
Cell therapies can potentially be regulated under either pathway, as described below:
361 products that meet all the criteria outlined in 21 CFR 1271.10(a) are regulated as HCT/Ps and are not required to be licensed or approved by the FDA. These products are called “361 products,” because they are regulated under Section 361 of the Public Health Service (PHS) Act.
In contrast, if a cell therapy product does not meet all the criteria outlined in 21 CFR 1271.10(a)), then it is regulated as a “drug, device, or biological product” under the Federal Food, Drug, and Cosmetic Act (FDCA) and Section 351 of the PHS Act. These 351 products require clinical trials to demonstrate safety and efficacy in a process that is nearly identical to that what is required for pharmaceutical products to enter the marketplace.
16154 Main Ave. #134, Prior Lake, MN 55372
Copyright © 2015 RegenLIFE - All Rights Reserved.
Regenlife does not claim that treatment using tissue therapy are a cure for any condition, disease, or injury. Regenerative cell therapy (Often referred to as “Stem cell therapy”) is not a part of FDA approved stem cell therapies and is not considered a cure for any medical condition. All statements and opinions provided on this website are for educational and informational purposes only and we do not diagnose or give medical advise via this website.
Individuals interested in regenerative cell therapy are urged to review all pertinent information and do their own research before choosing to participate in regenerative cell therapy. Please note, there is no guarantee of specific results with our care and results may vary. Please contact us to discuss your specific condition. Per FTC GUIDE LINES CONCERNING USE OF ENDORSEMENTS AND TESTIMONIALS IN ADVERTISING, PLEASE BE AWARE OF THE FOLLOWING: Federal regulation requires us to inform our customers that all product reviews, testimonials or endorsements of products sold & services received through our office reflects the personal experience of those individuals. They are expressing their personal opinions on our products and services and that those opinions and experiences may not be representative of what every consumer of our products may personally experience with the endorsed product.
All products and services reviews and testimonials are the sole opinions, findings or experiences of our customers and not those of our company. Our company does not compensate in any way for testimonials or reviews. These statements have not been evaluated by the US Food and Drug Administration (FDA). We are required to inform you that there is no intention, implied or otherwise that represents or infers that these products or statements be used in the cure, diagnosis, mitigation, treatment, or prevention of any disease.
These reviews & testimonials do not imply that similar results will happen with your use of our products. We have no competent or reliable scientific evidence to suggest that the testimonial provider’s experience is due to the use of our products. These testimonials are not intended to recommend as a diagnosis for specific illnesses or conditions, nor as a product to eliminate diseases or other medical conditions or complications. We make no medical claims as to the benefits of any of our products to improve medical conditions.